Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion ...

LH heads into Q1 earnings results with rising diagnostics demand, new partnerships, and AI-driven tools boosting growth ...

The yet-to-be-named new company will be publicly traded. Separating the laboratory testing work of LabCorp from the clinical trial services business, much of which came from acquisitions, will enable ...

Labcorp Holdings (LH) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

After hanging out the for sale sign and filing for bankruptcy earlier this year, the genetic testing provider Invitae has found a new home for its portfolio at Labcorp. The two companies announced ...

The deal includes outreach laboratory services in 13 states. CHS will continue to operate its inpatient and emergency department labs along with other hospital-based testing services. Like its chief ...

While the spinoff deal is positive for Labcorp, investors used the opportunity to sell on the news. Labcorp will do a $1 billion stock repurchase program and pay down debt. The company's revenues have ...

Optum.ai and Labcorp have announced a strategic collaboration to apply artificial intelligence to streamline laboratory operations, improve efficiency, and enhance patient and provider experiences.

Labcorp introduces US FDA-approved companion diagnostic to identify patients with ovarian cancer eligible for Keytruda: Burlington, North Carolina Friday, April 24, 2026, 13:00 Hr ...

Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and ...